SOURCE: Vitro Diagnostics, Inc.

November 27, 2007 08:00 ET

Vitro Appoints an Expert Toxicologist to Its Scientific Advisory Board

AURORA, CO--(Marketwire - November 27, 2007) - Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the appointment of Dr. Joe Nieusma to its Scientific Advisory Board. Dr. Nieusma earned his BS degree from Central Michigan University and Ph.D. from University of Colorado School of Pharmacy. He previously worked with Geneva/Sandoz Pharmaceuticals in Broomfield, CO as an industrial toxicologist and now operates Superior Toxicology and Wellness, an international consultant firm located in Superior, Colorado. He has extensive experience as an industrial toxicologist, an expert witness for drug-related litigation & chemical exposure cases and as an environmental health & safety professional.

Dr. Nieusma is presently a consultant to Vitro regarding business development and expansion of sales and marketing of existing and new products. Dr. Nieusma said, "I am pleased to be a member of Vitro's SAB where I believe that my extensive experience in pharmaceutical toxicology will be of benefit. I am especially excited about the prospects of the use of Vitro's stem cell-derived beta islets for applications in toxicological testing and drug development. Also, Vitro's stem cell technology is well-positioned to capitalize on opportunities for novel applications in therapy and pharmaceutical testing."

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) http://www.vitrodiag.com, has generated over 30 adult stem cell lines. These cell lines may have application in drug development and discovery, diabetes research and therapy; and also may contribute to newly discovered methods to produce embryonic-like stem cells from skin cells, a potential development that may allow use of adult cells to differentiate into any cell in the body and eliminate much of the current ethical concerns over human embryonic stem cells. The Company manufactures the VITROCELL™ brand of human pancreatic-derived cell lines and related products for research and commercial applications.

Safe Harbor Statement

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2006 under the caption, "Risk Factors" and subsequent SEC filings. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • CONTACT:
    Dr. James Musick
    Chief Executive Officer
    Vitro Diagnostics, Inc.
    (720) 859-4120
    E-mail: Email Contact